ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
FDA Approves IMBRUVICA® as First Treatment Specifically Indicated for Relapsed/Refractory Marginal Z
January 20, 2017AbbVie has announced that the U.S. Food and Drug Administration (FDA) approved IMBRUVICA® (ibrutinib) for the treatment of patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL) who require systemic therapy and have received at least one pri
Pharma Sources Insight January 2025
